ProCE Banner Activity

CME

Cancer Conversations™: How New Data Are Changing Current Therapeutic Algorithms in Melanoma

Multimedia
Watch this on-demand webcast of a live CCO webinar to hear a panel of experts discuss the changing treatment landscape in melanoma.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 29, 2021

Expiration: September 28, 2022

No longer available for credit.

Share

Faculty

Jeffrey S. Weber

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Hussein Tawbi

Hussein Tawbi, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.

Target Audience

This educational program is intended for oncologists and other healthcare professionals involved in the care of patients with melanoma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess clinical trial evidence to incorporate existing and recently approved adjuvant therapies in appropriately identified patients after surgical removal of primary melanoma
  • Determine key factors critical to aid the selection of adjuvant, first-line and later lines of therapy for patients with metastatic BRAF wild-type or BRAF-mutated melanoma
  • Appraise clinical trial evidence to optimize incorporation of targeted and immunotherapeutic approaches for metastatic BRAF-mutated melanoma including patients with brain metastases
  • Manage specific disease-related complications or adverse events associated with immune checkpoint inhibitors, targeted therapies, and other systemic treatments for melanoma and offer optimal management strategies to minimize adverse events
  • Evaluate ongoing clinical trials investigating anti–PD-1/PD-L1 antibodies in combination with other systemic therapies in advanced melanoma

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Jeffrey S. Weber, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Moderna, Novartis, and Pfizer.

Faculty Disclosure

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD, has disclosed that she has received consulting fees from BluePath Solutions, Iovance, Nanobiotix, Novartis, Pfizer, and Shanghai Jo’Ann Medical Technology.

Hussein Tawbi, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Hussein Tawbi, MD, PhD has disclosed that he has received consulting fees from Bristol-Myers Squibb, Eisai, Genentech/Roche, Iovance, Karyopharm, Merck, Novartis, and Pfizer and funds for research support (paid to his institution) from Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, and Novartis.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 29, 2021, through September 28, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate oncologists in hematology/oncology about the recent developments in the care of melanoma and incorporating new data and new therapies into their patient treatment plans.